Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TYRA | CLUSTER | bullish | 8/10 | Two Tyra Biosciences insiders, including 10% owner RA Capital Management, made open-market purchases totaling $200.01M f | Sep 16, 2026 |
| LODE | SC 13D/A | bearish | 5/10 | MAK Capital Fund LP filed Amendment No. 1 to its Schedule 13D on Comstock Inc. (LODE), reporting a reduction in its bene | Sep 16, 2026 |
| ACOG | INSIDER-BUY | bullish | 4/10 | Opaleye Management Inc., a 10% owner of Alpha Cognition, purchased 43.8K shares for $380K in open-market transactions on | Sep 16, 2026 |
| ERNA | 8-K | neutral | 2/10 | Ernexa Therapeutics Inc. filed an 8-K on September 16, 2026, disclosing a corporate fact sheet and an investor presentat | Sep 16, 2026 |
| VNRX | SC 13D/A | neutral | 3/10 | Lagoda Investment Management filed an amended Schedule 13D for VolitionRx, reporting a 5.9% stake (1,650,505 shares) as | Sep 16, 2026 |
| ADIL | DEFA14A | bullish | 6/10 | Adial Pharmaceuticals filed definitive additional proxy materials (DEFA14A) on September 16, 2026, amending the Securiti | Sep 16, 2026 |
| LGVN | PRESS-RELEASE | bearish | 7/10 | Longeveron announced that its Phase 2b ELPIS II trial of laromestrocel in HLHS failed to meet the primary endpoint (RVEF | Sep 16, 2026 |
| NUOX | S-1/A | neutral | 5/10 | NuvOx Therapeutics filed Amendment No. 1 to its S-1 registration statement for an IPO of 2,860,000 shares of common stoc | Sep 16, 2026 |
| MTNB | 8-K | neutral | 4/10 | Matinas BioPharma announced a 1-for-15 reverse stock split, effective September 28, 2026, to regain compliance with NYSE | Sep 16, 2026 |
| CLNN | 8-K | bearish | 6/10 | Clene Inc. entered into a securities purchase agreement for a $4.0 million registered direct offering of 1,219,513 share | Sep 16, 2026 |
| TVGN | 8-K | neutral | 3/10 | Tevogen granted its CEO and CFO performance-based restricted stock awards totaling 8.75 million shares, vesting only if | Sep 16, 2026 |
| ADIL | 8-K | bullish | 6/10 | Adial Pharmaceuticals amended its June 2026 Securities Purchase Agreement and Note Exchange Agreements to remove a Penal | Sep 16, 2026 |
| HURA | 8-K | neutral | 4/10 | TuHURA Biosciences adopted a 2026 Inducement Equity Incentive Plan, reserving 5,000,000 shares of common stock for equit | Sep 16, 2026 |
| SNYR | 8-K | bearish | 8/10 | Synergy CHC Corp. received a delisting notice from Nasdaq on September 11, 2026, following its Chapter 11 bankruptcy fil | Sep 16, 2026 |
| ERNA | 8-K | neutral | 2/10 | Ernexa Therapeutics appointed Robert J. Spiegel, M.D. to its board of directors, effective immediately. This is a routin | Sep 16, 2026 |
| MRNA | CLUSTER | bearish | 5/10 | Moderna CFO James Mock sold $4.68M in open-market shares on September 10, 2026, following option exercises, while Presid | Sep 16, 2026 |
| TPST | DEFA14A | neutral | 5/10 | Tempest Therapeutics adjourned its reconvened special meeting on September 15, 2026, again due to insufficient votes to | Sep 16, 2026 |
| LPCN | 8-K | neutral | 2/10 | Lipocine Inc. filed an 8-K to report that it presented at the H.C. Wainwright 28th Annual Global Investor Conference on | Sep 16, 2026 |
| TPST | 8-K | neutral | 4/10 | Tempest Therapeutics adjourned its reconvened special meeting of stockholders on September 15, 2026, because it lacked s | Sep 16, 2026 |
| KTTA | 8-K | neutral | 3/10 | Pasithea Therapeutics announced that its publicly traded warrants (KTTAW) will expire on September 17, 2026, and will ce | Sep 16, 2026 |
| GOSS | 8-K | neutral | 4/10 | Gossamer Bio appointed Gregory A. Ciongoli to its Board of Directors as a Class III director and Audit Committee member, | Sep 16, 2026 |
| PHVS | CLUSTER | bearish | 6/10 | Five Pharvaris insiders, including the CEO, President, and Chief Commercial Officer, collectively sold $2.93M in open-ma | Sep 16, 2026 |
| AQST | CLUSTER | neutral | 3/10 | Insider cluster at Aquestive (AQST) is dominated by a single open-market SELL from CCO Sherry Korczynski ($46K) plus a s | Sep 16, 2026 |
| CLNN | 424B5 | bearish | 5/10 | Clene Inc. is raising approximately $4.0 million in gross proceeds through a direct offering of 1,219,513 shares at $3.2 | Sep 16, 2026 |
| ABOS | 8-K | neutral | 3/10 | Acumen Pharmaceuticals filed an 8-K with Regulation FD disclosure (Item 7.01) and the accompanying exhibit (Item 9.01), | Sep 16, 2026 |
| XCUR | 8-K | bearish | 7/10 | Exicure, Inc. filed an 8-K with Item 3.01 disclosing a delisting notice from Nasdaq. The company received notice that it | Sep 16, 2026 |
| PRFX | 6-K | neutral | 4/10 | PRF Technologies announced via a 6-K filing that its GridFeed AI-driven energy optimization platform is exploring the AI | Sep 16, 2026 |
| ALKS | 8-K | neutral | 2/10 | Alkermes appointed Anne C. Whitaker as an independent director, expanding the board from 10 to 11 members. Ms. Whitaker | Sep 16, 2026 |
| OPTH | 6-K | bullish | 6/10 | Optimi Health announced plans for a Health Canada-authorized Phase 3 clinical trial evaluating MDMA-assisted therapy for | Sep 16, 2026 |
| OGEN | 8-K | neutral | 3/10 | Oragenics filed an 8-K announcing its Chief Medical Officer will present at the IPAC-RS 2026 Nasal Innovation Forum, hig | Sep 16, 2026 |